Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Oral Investigations
Published in: Clinical Oral Investigations 2/2015

01-03-2015 | Original Article

Azithromycin suppresses P. gingivalis LPS-induced pro-inflammatory cytokine and chemokine production by human gingival fibroblasts in vitro

Authors: C. J. Doyle, T. R. Fitzsimmons, C. Marchant, A. A. S. S. K. Dharmapatni, R. Hirsch, P. M. Bartold

Published in: Clinical Oral Investigations | Issue 2/2015

Login to get access

Abstract

Objective

Azithromycin is a macrolide antibiotic that appears to have both antibacterial and anti-inflammatory properties. This study aimed to investigate the effect of azithromycin on the production of pro-inflammatory cytokines and chemokines by human gingival fibroblasts (HGF) in vitro.

Materials and methods

The effects of azithromycin (0.1 to 10 μg/mL) on the production of interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), and growth-regulated oncogene (GRO) by human gingival fibroblasts cultured in the presence or absence of Porphyromonas gingivalis lipopolysaccharide (LPS) was studied. Cytokine and chemokine protein levels in the culture supernatant were assessed using a Luminex® multiplex immunoassay.

Results

P. gingivalis LPS induced cytokine/chemokine (IL-6, IL-8, MCP-1, and GRO) protein production in HGFs, and this effect was suppressed by azithromycin at all concentrations tested.

Conclusions

This study demonstrates that azithromycin suppresses P. gingivalis LPS-induced cytokine/chemokine protein production in HGF, which may explain some of the clinical benefits observed with the adjunctive use of azithromycin in the treatment of periodontitis.

Clinical relevance

The current study examines the anti-inflammatory properties of azithromycin which may make it useful as an adjunct treatment to periodontitis. Specifically, we used azithromycin to modulate the production of pro-inflammatory cytokines by gingival fibroblasts known to be important in periodontal inflammation.
Literature
1.
2.
Greenstein G (1992) Periodontal response to mechanical non-surgical therapy: a review. J Periodontol 63:118–130CrossRefPubMed
3.
Drisko CH (2001) Nonsurgical periodontal therapy. Periodontol 2000(25):77–88CrossRef
4.
Gomi K, Yashima A, Nagano T, Kanazashi M, Maeda N, Arai T (2007) Effects of full-mouth scaling and root planing in conjunction with systemically administered azithromycin. J Periodontol 78:422–429CrossRefPubMed
5.
Heitz-Mayfield LJ (2009) Systemic antibiotics in periodontal therapy. Aust Dent J 54(Suppl 1):S96–S101CrossRefPubMed
6.
Preshaw PM (2008) Host response modulation in periodontics. Periodontol 2000(48):92–110CrossRef
7.
Pajukanta R (1993) In vitro antimicrobial susceptibility of Porphyromonas gingivalis to azithromycin, a novel macrolide. Oral Microbiol Immunol 8:325–326CrossRefPubMed
8.
Pajukanta R, Asikainen S, Saarela M, Alaluusua S, Jousimies-Somer H (1992) In vitro activity of azithromycin compared with that of erythromycin against Actinobacillus actinomycetemcomitans. Antimicrob Agents Chemother 36:1241–1243CrossRefPubMedCentralPubMed
9.
Bartold PM, du Bois AH, Gannon S, Haynes DR, Hirsch RS (2013) Antibacterial and immunomodulatory properties of azithromycin treatment implications for periodontitis. Inflammopharmacology 21:321–338CrossRefPubMed
10.
Hirsch R, Deng H, Laohachai MN (2012) Azithromycin in periodontal treatment: more than an antibiotic. J Periodontal Res 47:137–148CrossRefPubMed
11.
Muniz FW, de Oliveira CC, de Sousa CR, Moreira MM, de Moraes ME, Martins RS (2013) Azithromycin: a new concept in adjuvant treatment of periodontitis. Eur J Pharmacol 705:135–139CrossRefPubMed
12.
Hirsch R (2010) Periodontal healing and bone regeneration in response to azithromycin. Aust Dent J 55:193–199CrossRefPubMed
13.
Schmidt EF, Bretz WA (2007) Benefits of additional courses of systemic azithromycin in periodontal disease case report. N Y State Dent J 73:40–45PubMed
14.
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG (2011) Immunomodulatory effects of macrolide antibiotics—part 1: biological mechanisms. Respir Int Rev Thorac Dis 81:67–74
15.
Kudoh S, Uetake T, Hagiwara K, Hirayama M, Hus LH, Kimura H, Sugiyama Y (1987) Clinical effects of low-dose long-term erythromycin chemotherapy on diffuse panbronchiolitis. Nihon Kyobu Shikkan Gakkai Zasshi 25:632–642PubMed
16.
Bartold PM, Van Dyke TE (2013) Periodontitis: a host-mediated disruption of microbial homeostasis. Unlearning learned concepts. Periodontol 2000(62):203–217CrossRef
17.
Kamemoto A, Ara T, Hattori T, Fujinami Y, Imamura Y, Wang PL (2009) Macrolide antibiotics like azithromycin increase lipopolysaccharide-induced IL-8 production by human gingival fibroblasts. Eur J Med Res 14:309–314CrossRefPubMedCentralPubMed
18.
Gannon SC, Cantley MD, Haynes DR, Hirsch R, Bartold PM (2013) Azithromycin suppresses human osteoclast formation and activity in vitro. J Cell Physiol 228:1098–1107CrossRefPubMed
19.
Takashiba S, Naruishi K, Murayama Y (2003) Perspective of cytokine regulation for periodontal treatment: fibroblast biology. J Periodontol 74:103–110CrossRefPubMed
20.
Scheres N, Laine ML, de Vries TJ, Everts V, van Winkelhoff AJ (2010) Gingival and periodontal ligament fibroblasts differ in their inflammatory response to viable Porphyromonas gingivalis. J Periodontal Res 45:262–270CrossRefPubMed
21.
Morandini AC, Sipert CR, Gasparoto TH, Greghi SL, Passanezi E, Rezende ML, Sant’ana AP, Campanelli AP, Garlet GP, Santos CF (2010) Differential production of macrophage inflammatory protein-1alpha, stromal-derived factor-1, and IL-6 by human cultured periodontal ligament and gingival fibroblasts challenged with lipopolysaccharide from P. gingivalis. J Periodontol 81:310–317CrossRefPubMed
22.
Ara T, Kurata K, Hirai K, Uchihashi T, Uematsu T, Imamura Y, Furusawa K, Kurihara S, Wang PL (2009) Human gingival fibroblasts are critical in sustaining inflammation in periodontal disease. J Periodontal Res 44:21–27CrossRefPubMed
23.
Jonsson D, Amisten S, Bratthall G, Holm A, Nilsson BO (2009) LPS induces GROalpha chemokine production via NF-kappaB in oral fibroblasts. Inflamm Res 58:791–796CrossRefPubMed
24.
Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T et al (1990) IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145:3297–3303PubMed
25.
Wada N, Maeda H, Yoshimine Y, Akamine A (2004) Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha. Bone 35:629–635CrossRefPubMed
26.
Mogi M, Otogoto J, Ota N, Inagaki H, Minami M, Kojima K (1999) Interleukin 1 beta, interleukin 6, beta 2-microglobulin, and transforming growth factor-alpha in gingival crevicular fluid from human periodontal disease. Arch Oral Biol 44:535–539CrossRefPubMed
27.
Fitzsimmons TR, Sanders AE, Slade GD, Bartold PM (2009) Biomarkers of periodontal inflammation in the Australian adult population. Aust Dent J 54:115–122CrossRefPubMed
28.
Yu X, Graves DT (1995) Fibroblasts, mononuclear phagocytes, and endothelial cells express monocyte chemoattractant protein-1 (MCP-1) in inflamed human gingiva. J Periodontol 66:80–88CrossRefPubMed
29.
Wang PL, Ohura K, Fujii T, Oido-Mori M, Kowashi Y, Kikuchi M, Suetsugu Y, Tanaka J (2003) DNA microarray analysis of human gingival fibroblasts from healthy and inflammatory gingival tissues. Biochem Biophys Res Commun 305:970–973CrossRefPubMed
30.
Wada N, Wang B, Lin NH, Laslett AL, Gronthos S, Bartold PM (2011) Induced pluripotent stem cell lines derived from human gingival fibroblasts and periodontal ligament fibroblasts. J Periodontal Res 46:438–447CrossRefPubMed
31.
Gomi K, Yashima A, Iino F, Kanazashi M, Nagano T, Shibukawa N, Ohshima T, Maeda N, Arai T (2007) Drug concentration in inflamed periodontal tissues after systemically administered azithromycin. J Periodontol 78:918–923CrossRefPubMed
32.
Lai PC, Ho W, Jain N, Walters JD (2011) Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration. J Periodontol 82:1582–1586CrossRefPubMedCentralPubMed
33.
Malizia T, Tejada MR, Ghelardi E, Senesi S, Gabriele M, Giuca MR, Blandizzi C, Danesi R, Campa M, Del Tacca M (1997) Periodontal tissue disposition of azithromycin. J Periodontol 68:1206–1209CrossRefPubMed
34.
35.
Ho W, Eubank T, Leblebicioglu B, Marsh C, Walters J (2010) Azithromycin decreases crevicular fluid volume and mediator content. J Dent Res 89:831–835CrossRefPubMedCentralPubMed
36.
Matsumura Y, Mitani A, Suga T, Kamiya Y, Kikuchi T, Tanaka S, Aino M, Noguchi T (2011) Azithromycin may inhibit interleukin-8 through suppression of Rac1 and a nuclear factor-kappa B pathway in KB cells stimulated with lipopolysaccharide. J Periodontol 82:1623–1631CrossRefPubMed
37.
Zhou J, Windsor LJ (2007) Heterogeneity in the collagen-degrading ability of Porphyromonas gingivalis-stimulated human gingival fibroblasts. J Periodontal Res 42:77–84CrossRefPubMed
38.
Retsema J, Girard A, Schelkly W, Manousos M, Anderson M, Bright G, Borovoy R, Brennan L, Mason R (1987) Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother 31:1939–1947CrossRefPubMedCentralPubMed
39.
Bartold PM, Narayanan AS (2006) Molecular and cell biology of healthy and diseased periodontal tissues. Periodontol 2000(40):29–49CrossRef
Metadata
Title
Azithromycin suppresses P. gingivalis LPS-induced pro-inflammatory cytokine and chemokine production by human gingival fibroblasts in vitro
Authors
C. J. Doyle
T. R. Fitzsimmons
C. Marchant
A. A. S. S. K. Dharmapatni
R. Hirsch
P. M. Bartold
Publication date
01-03-2015
Publisher
Springer Berlin Heidelberg
Published in
Clinical Oral Investigations / Issue 2/2015
Print ISSN: 1432-6981
Electronic ISSN: 1436-3771
DOI
https://doi.org/10.1007/s00784-014-1249-7

Other articles of this Issue 2/2015

Clinical Oral Investigations 2/2015 Go to the issue

Editorial

Prof. Wolfgang Gernet has handed over the baton to Prof. Daniel Edelhoff

Original Article

Macrophages and bisphosphonate-related osteonecrosis of the jaw (BRONJ): evidence of local immunosuppression of macrophages in contrast to other infectious jaw diseases

Original Article

Epstein–Barr virus associated peri-implantitis: a split-mouth study

Original Article

Surface scratch assessment of titanium implant abutments and cementum following instrumentation with metal curettes

Original Article

Effect of different curing protocols on the mechanical properties of low-viscosity bulk-fill composites

Original Article

Damage of lithium-disilicate all-ceramic restorations by an experimental self-adhesive resin cement used as core build-ups